Allergan's failed depression drug shows promise in opioid withdrawal FierceBiotech
Allergan's rapastinel, the centerpiece of its $560 million acquisition of Naurex, recently failed in pivotal trials in depression. But scientists at Duke University and ...
(CLICK HERE TO READ AND SEE MORE)
0 comments:
Post a Comment